Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials

GBE Jemec; M M Okun; S B Forman; WPF Gulliver; Errol Prens; U Mrowietz; A W Armstrong; Z Geng; Y Gu; DA Williams; HD Teixeira; AB Kimball

doi:10.1111/bjd.17919

Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials

GBE Jemec, M M Okun, S B Forman, WPF Gulliver, Errol Prens, U Mrowietz, A W Armstrong, Z Geng, Y Gu, DA Williams, HD Teixeira, AB Kimball

Dermatology

Research output: Contribution to journal › Article › Academic › peer-review

47 Citations (Scopus)

28 Downloads (Pure)

Original language	Undefined/Unknown
Journal	British Journal of Dermatology
DOIs	https://doi.org/10.1111/bjd.17919
Publication status	Published - 2019

Research programs

EMC OR-01

Access to Document

10.1111/bjd.17919

Repub_119268_O-A.pdfFinal published version, 297 KB

http://hdl.handle.net/1765/119268

Cite this

Jemec, GBE., Okun, M. M., Forman, S. B., Gulliver, WPF., Prens, E., Mrowietz, U., Armstrong, A. W., Geng, Z., Gu, Y., Williams, DA., Teixeira, HD., & Kimball, AB. (2019). Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials. British Journal of Dermatology. https://doi.org/10.1111/bjd.17919

@article{3afd9ca8e14c4e6dac2704f286da7ab6,

title = "Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials",

author = "GBE Jemec and Okun, \{M M\} and Forman, \{S B\} and WPF Gulliver and Errol Prens and U Mrowietz and Armstrong, \{A W\} and Z Geng and Y Gu and DA Williams and HD Teixeira and AB Kimball",

year = "2019",

doi = "10.1111/bjd.17919",

language = "Undefined/Unknown",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Oxford University Press",

}

Jemec, GBE, Okun, MM, Forman, SB, Gulliver, WPF, Prens, E, Mrowietz, U, Armstrong, AW, Geng, Z, Gu, Y, Williams, DA, Teixeira, HD & Kimball, AB 2019, 'Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials', British Journal of Dermatology. https://doi.org/10.1111/bjd.17919

TY - JOUR

T1 - Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials

AU - Jemec, GBE

AU - Okun, M M

AU - Forman, S B

AU - Gulliver, WPF

AU - Prens, Errol

AU - Mrowietz, U

AU - Armstrong, A W

AU - Geng, Z

AU - Gu, Y

AU - Williams, DA

AU - Teixeira, HD

AU - Kimball, AB

PY - 2019

Y1 - 2019

U2 - 10.1111/bjd.17919

DO - 10.1111/bjd.17919

M3 - Article

C2 - 30916379

SN - 0007-0963

JO - British Journal of Dermatology

JF - British Journal of Dermatology

ER -